Paper27042004
Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F and 1 other. Drug Des Devel Ther, 2016. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Selective use of sorafenib in the treatment of thyroid cancer. Papers, record 27042004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27042004
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Niacinamide | Major topic |
| Phenylurea Compounds | Major topic |
| Thyroid Neoplasms | Major topic |
| Cell Proliferation | |
| Humans | |
| Sorafenib |
Source PubMed
References85
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17940185 | BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. | Endocr Rev | 2007 | https://conductscience.org/library/papers/17940185 | PubMed |
| 2 | 20368568 | Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20368568 | PubMed |
| 3 | 21296855 | Global cancer statistics. | CA Cancer J Clin | 2011 | https://conductscience.org/library/papers/21296855 | PubMed |
| 4 | 19103722 | Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. | Eur J Endocrinol | 2009 | https://conductscience.org/library/papers/19103722 | PubMed |
| 5 | 19451442 | Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19451442 | PubMed |
| 6 | 24617711 | TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. | J Clin Endocrinol Metab | 2014 | https://conductscience.org/library/papers/24617711 | PubMed |
| 7 | 25572389 | Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. | Eur J Endocrinol | 2015 | https://conductscience.org/library/papers/25572389 | PubMed |
| 8 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 9 | 19773371 | Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | Eur J Endocrinol | 2009 | https://conductscience.org/library/papers/19773371 | PubMed |
| 10 | 24795243 | Definition and management of radioactive iodine-refractory differentiated thyroid cancer. | Lancet Diabetes Endocrinol | 2014 | https://conductscience.org/library/papers/24795243 | PubMed |
| 11 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 12 | 16303836 | Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. | J Clin Endocrinol Metab | 2006 | https://conductscience.org/library/papers/16303836 | PubMed |
| 13 | 24780046 | High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. | J Clin Endocrinol Metab | 2014 | https://conductscience.org/library/papers/24780046 | PubMed |
| 14 | 24728162 | Response to sorafenib treatment in advanced metastatic thyroid cancer. | Arq Bras Endocrinol Metabol | 2014 | https://conductscience.org/library/papers/24728162 | PubMed |
| 15 | 17519900 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17519900 | PubMed |
| 16 | 25029414 | Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. | J Clin Endocrinol Metab | 2014 | https://conductscience.org/library/papers/25029414 | PubMed |
| 17 | 7529046 | The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. | Genes Chromosomes Cancer | 1994 | https://conductscience.org/library/papers/7529046 | PubMed |
| 18 | 23125304 | Sorafenib therapy decreases the clearance of thyrotropin. | Eur J Endocrinol | 2013 | https://conductscience.org/library/papers/23125304 | PubMed |
| 19 | 22033631 | Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. | Ann Surg Oncol | 2012 | https://conductscience.org/library/papers/22033631 | PubMed |
| 20 | 19942992 | Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. | Arq Bras Endocrinol Metabol | 2009 | https://conductscience.org/library/papers/19942992 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42688036 | Transcriptomic profiling of thyroid eye disease orbital fibroblasts identifies sorafenib as a novel therapeutic. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42688036 | PubMed |
| 41642503 | Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41642503 | PubMed |
| 40647542 | Oncogenic Activity and Sorafenib Sensitivity of ARAF p.S214C Mutation in Lung Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647542 | PubMed |
| 39790707 | Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review). | Med Int (Lond) | 2025 | https://conductscience.org/library/papers/39790707 | PubMed |
| 39109434 | Anti-proliferation evaluation of new derivatives of indole-6-carboxylate ester as receptor tyrosine kinase inhibitors. | Future Med Chem | 2024 | https://conductscience.org/library/papers/39109434 | PubMed |
| 38298714 | Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice. | Heliyon | 2024 | https://conductscience.org/library/papers/38298714 | PubMed |
| 37513950 | Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513950 | PubMed |
| 37323919 | Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. | Saudi Pharm J | 2023 | https://conductscience.org/library/papers/37323919 | PubMed |
| 36983412 | Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer. | J Clin Med | 2023 | https://conductscience.org/library/papers/36983412 | PubMed |
| 36003403 | Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review. | Front Immunol | 2022 | https://conductscience.org/library/papers/36003403 | PubMed |
| 35680841 | Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression. | Cell Death Discov | 2022 | https://conductscience.org/library/papers/35680841 | PubMed |
| 35630083 | Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review. | Medicina (Kaunas) | 2022 | https://conductscience.org/library/papers/35630083 | PubMed |
| 35445315 | Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. | Cancer Chemother Pharmacol | 2022 | https://conductscience.org/library/papers/35445315 | PubMed |
| 35335280 | Enhancing the Anticancer Activity of Sorafenib through Its Combination with a Nitric Oxide Photodelivering β-Cyclodextrin Polymer. | Molecules | 2022 | https://conductscience.org/library/papers/35335280 | PubMed |
| 35281942 | Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35281942 | PubMed |
| 34984230 | Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case. | Arch Clin Cases | 2021 | https://conductscience.org/library/papers/34984230 | PubMed |
| 34335481 | Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34335481 | PubMed |
| 34239388 | Metastatic Papillary Thyroid Cancer to the Liver: The Central Role of a Multidisciplinary Approach to Treatment. | Ochsner J | 2021 | https://conductscience.org/library/papers/34239388 | PubMed |
| 33655469 | YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. | Cell Oncol (Dordr) | 2021 | https://conductscience.org/library/papers/33655469 | PubMed |
| 33622865 | Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells In Vitro. | In Vivo | 2021 | https://conductscience.org/library/papers/33622865 | PubMed |
Genes23
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27042004
GET https://conductscience.org/api/papers/v1/27042004/references?page=2